JP2022510207A5 - - Google Patents

Info

Publication number
JP2022510207A5
JP2022510207A5 JP2021530163A JP2021530163A JP2022510207A5 JP 2022510207 A5 JP2022510207 A5 JP 2022510207A5 JP 2021530163 A JP2021530163 A JP 2021530163A JP 2021530163 A JP2021530163 A JP 2021530163A JP 2022510207 A5 JP2022510207 A5 JP 2022510207A5
Authority
JP
Japan
Prior art keywords
cells
derived
cell
antigen
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021530163A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022510207A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/063024 external-priority patent/WO2020117526A1/en
Publication of JP2022510207A publication Critical patent/JP2022510207A/ja
Publication of JP2022510207A5 publication Critical patent/JP2022510207A5/ja
Priority to JP2025018442A priority Critical patent/JP2025072543A/ja
Pending legal-status Critical Current

Links

JP2021530163A 2018-12-02 2019-11-25 増強されたiPSC派生エフェクター細胞を使用した免疫療法 Pending JP2022510207A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025018442A JP2025072543A (ja) 2018-12-02 2025-02-06 増強されたiPSC派生エフェクター細胞を使用した免疫療法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862774278P 2018-12-02 2018-12-02
US62/774,278 2018-12-02
PCT/US2019/063024 WO2020117526A1 (en) 2018-12-02 2019-11-25 IMMUNOTHERAPIES USING ENHANCED iPSC DERIVED EFFECTOR CELLS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025018442A Division JP2025072543A (ja) 2018-12-02 2025-02-06 増強されたiPSC派生エフェクター細胞を使用した免疫療法

Publications (2)

Publication Number Publication Date
JP2022510207A JP2022510207A (ja) 2022-01-26
JP2022510207A5 true JP2022510207A5 (cg-RX-API-DMAC7.html) 2022-12-12

Family

ID=70974390

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021530163A Pending JP2022510207A (ja) 2018-12-02 2019-11-25 増強されたiPSC派生エフェクター細胞を使用した免疫療法
JP2025018442A Pending JP2025072543A (ja) 2018-12-02 2025-02-06 増強されたiPSC派生エフェクター細胞を使用した免疫療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025018442A Pending JP2025072543A (ja) 2018-12-02 2025-02-06 増強されたiPSC派生エフェクター細胞を使用した免疫療法

Country Status (12)

Country Link
US (1) US12435123B2 (cg-RX-API-DMAC7.html)
EP (1) EP3891177A4 (cg-RX-API-DMAC7.html)
JP (2) JP2022510207A (cg-RX-API-DMAC7.html)
KR (1) KR102943217B1 (cg-RX-API-DMAC7.html)
CN (1) CN113166232A (cg-RX-API-DMAC7.html)
AU (1) AU2019392265B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021010331A2 (cg-RX-API-DMAC7.html)
CA (1) CA3121128A1 (cg-RX-API-DMAC7.html)
IL (1) IL283607A (cg-RX-API-DMAC7.html)
MX (1) MX2021006194A (cg-RX-API-DMAC7.html)
SG (1) SG11202105480WA (cg-RX-API-DMAC7.html)
WO (1) WO2020117526A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230040337A (ko) * 2020-06-19 2023-03-22 페이트 세러퓨틱스, 인코포레이티드 면역요법 사용을 위한 iPSC-유래 이펙터 세포 유형들의 조합
CN114525255A (zh) * 2020-10-30 2022-05-24 未来智人再生医学研究院(广州)有限公司 一种表达il-11的多能干细胞衍生物及其应用
WO2022098914A1 (en) * 2020-11-04 2022-05-12 Fate Therapeutics, Inc. Engineered ipsc and persistent immune effector cells
US20230405121A1 (en) * 2020-11-04 2023-12-21 Fate Therapeutics, Inc. Engineered ipsc and immune effector cells for heterogenous tumor control
US11459372B2 (en) 2020-11-30 2022-10-04 Crispr Therapeutics Ag Gene-edited natural killer cells
IL303269A (en) 2020-12-03 2023-07-01 Century Therapeutics Inc Genetically engineered cells and uses thereof
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
TW202241935A (zh) 2020-12-18 2022-11-01 美商世紀治療股份有限公司 具有可調適受體專一性之嵌合抗原受體系統
EP4271798A1 (en) 2020-12-30 2023-11-08 CRISPR Therapeutics AG Compositions and methods for differentiating stem cells into nk cells
MX2023008809A (es) * 2021-01-29 2023-08-04 Allogene Therapeutics Inc ATENUACIÓN O INACTIVACIÓN DE UNO O MÁS DE TAP2, NLRC5, ß2M, TRAC, RFX5, RFXAP Y RFXANK PARA MITIGAR EL RECONOCIMIENTO DE CÉLULAS T DE PRODUCTOS CELULARES ALOGÉNICOS.
WO2022179620A1 (zh) * 2021-02-25 2022-09-01 克莱格医学有限公司 Cd94工程化细胞及其组合物
CA3214473A1 (en) * 2021-04-07 2022-10-13 Century Therapeutics, Inc. Compositions and methods for generating alpha-beta t cells from induced pluripotent stem cells
JP2024522756A (ja) * 2021-06-18 2024-06-21 オーエヌケイ セラピューティクス リミテッド ダブルノックアウトナチュラルキラー細胞
US20240307540A1 (en) * 2021-07-02 2024-09-19 Fate Therapeutics, Inc. Protected effector cells and use thereof for allogeneic adoptive cell therapies
WO2023093763A1 (en) * 2021-11-24 2023-06-01 Hangzhou Qihan Biotechnology Co., Ltd. Systems and methods for cell-based immunotherapies cross-reference
EP4353741A1 (en) * 2022-10-14 2024-04-17 ONK Therapeutics Limited Double knockout natural killer cells
WO2024183750A1 (en) * 2023-03-07 2024-09-12 Qihan Hong Kong Limited A novel immune cell and use thereof for treating diseases
WO2025189046A2 (en) * 2024-03-06 2025-09-12 The Johns Hopkins University Pantigen specific cytokine receptor stimulation of immune cell function

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9710809D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
GB9710807D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
GB9725764D0 (en) * 1997-12-04 1998-02-04 Isis Innovation HLA-E binding
US6140081A (en) 1998-10-16 2000-10-31 The Scripps Research Institute Zinc finger binding domains for GNN
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
JP2002060786A (ja) 2000-08-23 2002-02-26 Kao Corp 硬質表面用殺菌防汚剤
US20040224385A1 (en) 2001-08-20 2004-11-11 Barbas Carlos F Zinc finger binding domains for cnn
US7745140B2 (en) 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US7972854B2 (en) 2004-02-05 2011-07-05 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
AU2005250408B2 (en) 2004-05-27 2010-09-23 The Trustees Of The University Of Pennsylvania Novel artificial antigen presenting cells and uses therefor
CN105837690A (zh) 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
US7932055B2 (en) 2006-06-22 2011-04-26 Novo Nordisk A/S Soluble heterodimeric CD94/NKG2 receptors fusion proteins
PT2816112T (pt) 2009-12-10 2018-11-20 Univ Iowa State Res Found Inc Modificação do adn modificada pelo efector tal
WO2011159726A2 (en) 2010-06-14 2011-12-22 The Scripps Research Institute Reprogramming of cells to a new fate
MX2014001222A (es) 2011-07-29 2014-09-15 Univ Pennsylvania Receptores coestimuladores de cambio.
EP2814846B1 (en) 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
SG10201806573TA (en) 2012-05-25 2018-09-27 Cellectis Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
IL305629A (en) 2013-02-15 2023-11-01 Univ California Chimeric antigen receptor and methods of using it
US9932607B2 (en) 2013-11-15 2018-04-03 The Board Of Trustees Of The Leland Stanford Junior University Site-specific integration of transgenes into human cells
EP3104866A4 (en) 2014-02-14 2017-08-02 Bellicum Pharmaceuticals, Inc. Methods for activating t cells using an inducible chimeric polypeptide
DK3105335T3 (da) 2014-02-14 2020-01-13 Univ Texas Kimære antigenreceptorer og fremgangsmåder til fremstilling heraf
CN120536341A (zh) 2014-03-04 2025-08-26 菲特治疗公司 改良的重编程方法和细胞培养平台
CN113699159A (zh) 2014-03-28 2021-11-26 明尼苏达大学评议会 涉及经工程改造的cd16的多肽、细胞和方法
AU2015312117A1 (en) 2014-09-02 2017-03-02 Bellicum Pharmaceuticals, Inc. Costimulation of chimeric antigen receptors by Myd88 and CD40 polypeptides
CN117737124A (zh) 2015-10-16 2024-03-22 菲特治疗公司 用于诱导和维护基态多能性的平台
CN122146606A (zh) 2015-11-04 2026-06-05 菲特治疗公司 用于诱导造血细胞分化的方法和组合物
CA3007473A1 (en) 2015-12-14 2017-06-22 Bellicum Pharmaceuticals, Inc. Dual controls for therapeutic cell activation or elimination
AU2017210031C1 (en) 2016-01-20 2020-11-26 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
BR112020011017A2 (pt) 2017-12-22 2020-11-17 Fate Therapeutics, Inc. células efetoras imunes intensificadas e uso das mesmas

Similar Documents

Publication Publication Date Title
JP2022548943A5 (cg-RX-API-DMAC7.html)
JP2021505131A5 (cg-RX-API-DMAC7.html)
JP2022541441A5 (cg-RX-API-DMAC7.html)
JP2022550899A5 (cg-RX-API-DMAC7.html)
US20260055157A1 (en) Methods of making chimeric antigen receptor-expressing cells
JP2023530704A5 (cg-RX-API-DMAC7.html)
CN112029001B (zh) 靶向nk激活性受体的嵌合抗原受体
JP2023505206A5 (cg-RX-API-DMAC7.html)
JP2021519061A5 (cg-RX-API-DMAC7.html)
JP2023549098A5 (cg-RX-API-DMAC7.html)
JP2023548467A5 (cg-RX-API-DMAC7.html)
AU2015374296B2 (en) Methods of making chimeric antigen receptor-expressing cells
JP2021040652A (ja) Gタンパク質共役受容体を標的化するキメラ抗原受容体およびその使用
CN114761425A (zh) 用于免疫效应细胞工程化的增强的嵌合抗原受体和其用途
JP2023548829A5 (cg-RX-API-DMAC7.html)
EP4506036A2 (en) Chimeric antigen receptors targeting fc receptor-like 5 and uses thereof
JP2023545992A5 (cg-RX-API-DMAC7.html)
CN111787938A (zh) 靶向bcma的嵌合抗原受体、靶向cd19的嵌合抗原受体及组合疗法
CN114901693A (zh) 用于免疫效应细胞工程化的增强的嵌合抗原受体和其用途
JP2022510207A (ja) 増強されたiPSC派生エフェクター細胞を使用した免疫療法
JP2023029624A (ja) strepタグ特異的キメラ受容体およびその使用
JP2024502157A (ja) 樹状細胞活性化キメラ抗原受容体及びその使用
KR102883294B1 (ko) 조작된 iPSC 및 보강된 면역 효과기 세포
JP2024533375A5 (cg-RX-API-DMAC7.html)
AU2021338819A1 (en) Chimeric antigen receptor comprising novel co-stimulatory domain and use thereof